NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.

In a report released today, from Wells Fargo maintained a Buy rating on NewAmsterdam Pharma Company, with a price target of $45.00. Currently, the ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NAMS	$35.07	0.00%	425.94K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NAMS	$35.07	0%	425.94K
3
4
5
6

NAMS

NAMS

No Data Available

Get NewAmsterdam Pharma Company N.V. Data in Excel

Get NewAmsterdam Pharma Company N.V. Data in Excel